634 related articles for article (PubMed ID: 31630815)
1. Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.
Keshishian A; Xie L; Dembek C; Yuce H
Clin Ther; 2019 Nov; 41(11):2283-2296. PubMed ID: 31630815
[TBL] [Abstract][Full Text] [Related]
2. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
3. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.
Celli BR; Navaie M; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
Int J Chron Obstruct Pulmon Dis; 2019; 14():1019-1031. PubMed ID: 31190787
[No Abstract] [Full Text] [Related]
4. Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease.
Gilmer TP; Celli BR; Xu Z; Cho-Reyes S; Dembek C; Navaie M
COPD; 2019 Apr; 16(2):140-151. PubMed ID: 31215259
[TBL] [Abstract][Full Text] [Related]
5. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
[TBL] [Abstract][Full Text] [Related]
6. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy V; Stensland MD
Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
[TBL] [Abstract][Full Text] [Related]
7. Trends and Factors Associated with Nebulized Therapy Prescription in Older Adults with Chronic Obstructive Pulmonary Disease from 2008 to 2015.
Singh M; Duarte AG; Hsu ES; Kuo YF; Sharma G
J Aerosol Med Pulm Drug Deliv; 2020 Jun; 33(3):161-169. PubMed ID: 32017642
[No Abstract] [Full Text] [Related]
8. Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.
Bishwakarma R; Zhang W; Kuo YF; Sharma G
Int J Chron Obstruct Pulmon Dis; 2017; 12():477-486. PubMed ID: 28203071
[TBL] [Abstract][Full Text] [Related]
9. Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.
Navaie M; Celli BR; Xu Z; Cho-Reyes S; Dembek C; Gilmer TP
Chronic Obstr Pulm Dis; 2019 Oct; 6(4):297-307. PubMed ID: 31483988
[TBL] [Abstract][Full Text] [Related]
10. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.
Sharafkhaneh A; Altan AE; Colice GL; Hanania NA; Donohue JF; Kurlander JL; Rodriguez-Roisin R; Altman PR
Respir Med; 2014 Sep; 108(9):1310-20. PubMed ID: 25130680
[TBL] [Abstract][Full Text] [Related]
11. Chronic obstructive pulmonary disease: prevalence, characteristics, and pharmacologic treatment in nursing home residents with cognitive impairment.
Zarowitz BJ; O'Shea T
J Manag Care Pharm; 2012 Oct; 18(8):598-606. PubMed ID: 23127147
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Veterans Admitted to the Hospital for Chronic Obstructive Pulmonary Disease Exacerbation.
Bade BC; DeRycke EC; Ramsey C; Skanderson M; Crothers K; Haskell S; Bean-Mayberry B; Brandt C; Bastian LA; Akgün KM
Ann Am Thorac Soc; 2019 Jun; 16(6):707-714. PubMed ID: 30822098
[No Abstract] [Full Text] [Related]
13. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.
Loh CH; Donohue JF; Ohar JA
Expert Opin Drug Saf; 2015 Mar; 14(3):463-72. PubMed ID: 25563342
[TBL] [Abstract][Full Text] [Related]
14. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
[TBL] [Abstract][Full Text] [Related]
15. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy.
Bollu V; Ejzykowicz F; Rajagopalan K; Karafilidis J; Hay JW
J Med Econ; 2013 Aug; 16(8):1082-8. PubMed ID: 23777224
[TBL] [Abstract][Full Text] [Related]
16. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
17. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
[TBL] [Abstract][Full Text] [Related]
18. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
19. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
20. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
